Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yogesh K. Chutake
Observed names:
Y. Chutake,
Y. K. Chutake,
Yogesh Chutake,
Yogesh K Chutake
Institution:
Accent Therapeutics (United States)
Observed institutions:
Accent Therapeutics (United States),
Syros Pharmaceuticals (United States),
University of Oklahoma Health Sciences Center,
University of Oklahoma
ORCID:
0009-0007-0531-8877
Observed ORCID:
0009-0007-0531-8877
OpenAlex ID:
A5031825744
Epigenetic Silencing in Friedreich Ataxia Is Associated with Depletion of CTCF (CCCTC-Binding Factor) and Antisense Transcription
2009
·
Irene De Biase
, Yogesh K. Chutake
, et al.
·
PLoS ONE
·
120
PDF
A novel GAA repeat expansion-based mouse model of Friedreich ataxia
2015
·
Sara Anjomani Virmouni
, Vahid Ezzatizadeh
, et al.
·
Disease Models & Mechanisms
·
71
PDF
Epigenetic promoter silencing in F riedreich ataxia is dependent on repeat length
2014
·
Yogesh K. Chutake
, Christina Lam
, et al.
·
Annals of Neurology
·
53
Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia
2020
·
Layne N Rodden
, Yogesh K Chutake
, et al.
·
Human Molecular Genetics
·
52
PDF
Altered Nucleosome Positioning at the Transcription Start Site and Deficient Transcriptional Initiation in Friedreich Ataxia
2014
·
Yogesh K. Chutake
, Whitney N. Costello
, et al.
·
Journal of Biological Chemistry
·
48
PDF
ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells
2022
·
Arthur W. Lambert
, Christopher Fiore
, et al.
·
Developmental Cell
·
35
PDF
The Cerebellar Cognitive Affective Syndrome in Ataxia-Telangiectasia
2018
·
Franziska Hoche
, Maureen P. Daly
, et al.
·
The Cerebellum
·
31
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2024
·
Yogesh K. Chutake
, Michele F. Mayo
, et al.
·
Molecular Cancer Therapeutics
·
29
PDF
Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor
2016
·
Yogesh K. Chutake
, Christina C. Lam
, et al.
·
Nucleic Acids Research
·
29
PDF
FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia
2015
·
Yogesh K. Chutake
, Whitney N. Costello
, et al.
·
PLoS ONE
·
21
PDF
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
2022
·
Michele Mayo
, Yogesh Chutake
, et al.
·
Blood
·
13
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
2024
·
M. Rizwan Rizwan-ul-Haq Khawaja
, Abdul Rafeh Naqash
, et al.
·
Journal of Clinical Oncology
·
11
Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
2022
·
Yogesh Chutake
, Michele Mayo
, et al.
·
Cancer Research
·
9
Deficiency of RecA-dependent RecFOR and RecBCD pathways causes increased instability of the (GAA{middle dot}TTC)n sequence when GAA is the lagging strand template
2007
·
L. M. Pollard
, Y. K. Chutake
, et al.
·
Nucleic Acids Research
·
9
A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia
2023
·
Samarpana Chakraborty
, Claudia Morganti
, et al.
·
Blood
·
7
KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells
2024
·
Min Lu
, Lijuan Xia
, et al.
·
Blood
·
3
Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models
2026
·
Varsha Ananthapadmanabhan
, Simone Bruno
, et al.
·
Journal of Clinical Investigation
·
2
PDF
A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.
2026
·
Judy S. Wang
, Ildefonso I. Rodriguez Rivera
, et al.
·
Journal of Clinical Oncology
·
1
PDF
295 (PB283): Predictive Markers of Response to the MDM2 Degrader KT-253
2024
·
N. Dumont
, R. Karnik
, et al.
·
European Journal of Cancer
·
1
P464: Pulse Dosing of Potent and Selective Heterobifunctional Mdm2 Degrader Kt-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to P53/mdm2 Small Molecule Inhibitors.
2023
·
Stefanie Schalm
, Yogesh Chutake
, et al.
·
HemaSphere
·
1
Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma
2020
·
Haojing Rong
, Kirti Sharma
, et al.
·
Blood
·
1
RNA-mediated transcriptional gene silencing in Friedreich ataxia
2011
·
Sanjay Bidichandani
, Angela Castro
, et al.
·
Current Opinion in Biotechnology
·
1
KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells
2026
·
Min Lu
, Lijuan Xia
, et al.
·
Leukemia
PDF
Abstract B070: ATX-295, a Novel KIF18A Inhibitor, as a Therapeutic in Chromosomally Instable Tumors
2026
·
Sunaina Nayak
, Maureen M. Lynes
, et al.
·
Clinical Cancer Research
Supplemental Table 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2026
·
Yogesh K. Chutake
, Michele F. Mayo
, et al.
Show more works
View as search
Works count:
53
Citation count:
548
H-index:
11
I10-index:
12
Year
Topic
Type
